Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

COMy 2022 | Advances in screening capabilities for precursor conditions

Sigurdur Kristinsson • 12 May 2022
COMy 2022
Multiple Myeloma Rare Diseases Smoldering Myeloma

In this video, Sigurdur Kristinsson, MD, PhD, University of Iceland, Reykjavík, Iceland, briefly discusses advances in screening capabilities for precursor conditions, highlighting the use of protein electrophoresis, immunofixation, and more recently, mass spectrometry. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.

Disclosures

Gelgene, Amgen

More from Sigurdur Kristinsson

Treating smoldering myeloma and the importance of improving patient selection 1:21
Treating smoldering myeloma and the importance of improving patient selection
Sigurdur Kristinsson • 25 Sep 2024
Key takeaways from the iStopMM trial: screening for MGUS 2:04
Key takeaways from the iStopMM trial: screening for MGUS
Sigurdur Kristinsson • 25 Sep 2024
iStopMM analysis results: autoimmune diseases are not associated with MGUS 2:47
iStopMM analysis results: autoimmune diseases are not associated with MGUS
Sigurdur Kristinsson • 12 Dec 2022
Evaluating whether SARS-CoV-2 vaccination has an impact on risk of progression from MGUS to myeloma 1:51
Evaluating whether SARS-CoV-2 vaccination has an impact on risk of progression from MGUS to myeloma
Sigurdur Kristinsson • 12 Dec 2022

Related Videos

Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8 4:02
Belantamab mafodotin in functional high-risk RRMM: subgroup analysis of DREAMM-7 and DREAMM-8
Meral Beksac • 10 Dec 2025
Incidence and risk factors for infections in NDMM treated with modern induction regimens 1:54
Incidence and risk factors for infections in NDMM treated with modern induction regimens
Efstathios Kastritis • 7 Dec 2025
A real-world analysis of infections in patients with RRMM receiving ide-cel 3:59
A real-world analysis of infections in patients with RRMM receiving ide-cel
Muhammad Bilal Abid • 6 Dec 2025
Integrating molecular diagnostics in smoldering myeloma to predict disease progression 1:37
Integrating molecular diagnostics in smoldering myeloma to predict disease progression
Gareth Morgan • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals